SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells 3,000 Shares

Key Points

• Insider selling: Zhenyu Xu sold 3,000 SOPHiA GENETICS shares for $21,000 under a pre-arranged Rule 10b5-1 plan, reducing the position by 0.50%. Xu also reported several other sales recently but still owns 600,887 shares.
• Quarterly results: The company reported a quarterly loss of $0.26 per share, missing the $0.21 loss estimate, although revenue of $23.31 million exceeded expectations of $21.72 million. SOPHiA GENETICS remains deeply unprofitable.
• Stock and analyst outlook: Shares rose to $7.71, near their 52-week high, after HC Wainwright and BTIG Research raised their price targets to $14 and $9, respectively. Despite mostly favorable analyst ratings, the consensus remains Hold with an average target of $10.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 3,000 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $7.00, for a total transaction of $21,000.00. Following the transaction, the insider owned 600,887 shares of the company's stock, valued at approximately $4,206,209. The trade was a 0.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total transaction of $69,200.00.
• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $22,800.00.
• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81.

SOPHiA GENETICS Stock Performance

SOPHiA GENETICS stock traded up $1.02 during trading on Friday, hitting $7.71. The stock had a trading volume of 963,487 shares, compared to its average volume of 220,563. The stock's 50 day moving average is $5.57 and its two-hundred day moving average is $5.13. SOPHiA GENETICS SA has a 1 year low of $2.96 and a 1 year high of $7.86. The stock has a market cap of $646.79 million, a price-to-earnings ratio of -6.70 and a beta of 0.96. The company has a quick ratio of 1.90, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. As a group, analysts predict that SOPHiA GENETICS SA will post -0.58 EPS for the current year.

Analyst Ratings Changes

SOPH has been the subject of a number of research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. HC Wainwright boosted their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Wednesday. BTIG Research upped their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Zacks Research raised shares of SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $10.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SOPH. Perkins Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at about $49,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS in the third quarter worth about $49,000. First Dallas Securities Inc. bought a new position in shares of SOPHiA GENETICS in the first quarter valued at approximately $50,000. Quadrature Capital Ltd purchased a new position in SOPHiA GENETICS during the fourth quarter valued at approximately $54,000. Finally, XTX Topco Ltd purchased a new position in SOPHiA GENETICS during the fourth quarter valued at approximately $55,000. Hedge funds and other institutional investors own 31.59% of the company's stock.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG Research raised its price target for SOPH from $8 to $9 while maintaining a Buy rating. The move adds to recent analyst support and reinforces the stock’s upward momentum. BTIG Research raises SOPHiA GENETICS price target
• Positive Sentiment: SOPHiA GENETICS reached a new 12-month high following the analyst upgrade, indicating strong investor demand and a favorable near-term trading reaction. SOPHiA GENETICS reaches a new 12-month high
• Positive Sentiment: HC Wainwright continues to rate SOPH Buy with a $14 price target, well above recent trading levels. Its longer-term forecast still calls for a return to profitability, including positive EPS estimates for 2029 and 2030.
• Neutral Sentiment: Chief Technology Officer Abhimanyu Verma sold 5,000 shares for approximately $34,750 under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance and reduced his ownership by only 2.6%, it carries limited signaling value.
• Negative Sentiment: HC Wainwright lowered EPS estimates across several periods: Q3 2026 to $(0.13), FY2026 to $(0.77) from $(0.58), FY2027 to $(0.31) from $(0.20), and FY2028 to $(0.02) from positive $0.04. Estimates for Q1–Q4 2027 were also reduced, suggesting profitability may arrive later than previously expected.
• Negative Sentiment: The company’s latest quarterly loss of $(0.26) per share exceeded the expected $(0.21) loss, highlighting ongoing profitability pressure despite revenue exceeding expectations. SOPH remains deeply unprofitable, which could limit further gains if growth or the path to breakeven weakens.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source